Glycation inactivation of the complement regulatory protein CD59: A possible role in the pathogenesis of the vascular complications of human diabetes

Diabetes

Volumn 53, Issue 10, 2004, Pages 2653-2661

  Qin, Xuebin ^a,b   Goldfine, Allison ^c   Krumrei, Nicole ^b   Grubissich, Luciano ^b   Acosta, Juan ^b,d   Chorev, Michael ^b   Hays, Arthur P ^e   Halperin, Jose A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMPLEMENT SYSTEM; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; ERYTHROCYTE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION;

AGED; ANTIBODY SPECIFICITY; ANTIGENS, CD; ANTIGENS, CD59; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; GLYCOSYLATION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; RECOMBINANT PROTEINS;

EID: 4644304889     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.10.2653     Document Type: Article

References (50)

1. DCCT Research Group: Diabetes Control and Complications Trial (DCCT): update. Diabetes Care 13:427-433, 1990
2. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. Nagaraj RH, Portero-Otin M, Monnier VM: Pyrraline ether crosslinks as a basis for protein crosslinking by the advanced Maillard reaction in aging and diabetes. Arch Biochem Biophys 325:152-158, 1996
4. Giardino I, Edelstein D, Brownlee M: Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 94:110-117, 1994
5. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
6. Reifsnyder PC, Churchill G, Leiter EH: Maternal environment and genotype interact to establish diabesity in mice. Genome Res 10:1568-1578, 2000
7. Velasquez MT, Kimmel PL, Michaelis OE 4th: Animal models of spontaneous diabetic kidney disease. FASEB J 4:2850-2859, 1990
8. Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, Angarita L, Halperin J: Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A 97:5450-5455, 2000
9. Mayer MM: Complement: historical perspective and some current issues. Complement 1:2-26, 1984
10. Halperin JA, Nicholson-Weller A, Brugnara C, Tosteson DC: Complement induces a transient increase in membrane permeability in unlysed erythrocytes. J Clin Invest 82:594-600, 1988
11. Halperin JA, Taratuska A, Rynkiewicz M, Nicholson-Weller A: Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood 81:200-205, 1993
12. Acosta JA, Benzzaquen LR, Goldstein DJ, Tosteson MT, Halperin JA: The transient pore formed by homologous terminal complement complexes functions as a bidirectional route for the transport of autocrine and paracrine signals across human cell membranes. Mol Med 2:755-765, 1996
13. Nicholson-Weller A, Halperin JA: Membrane signaling by complement C5b-9, the membrane attack complex. Immunol Res 12:244-257, 1993
14. Ward PA: Role of complement, chemokines, and regulatory cytokines in acute lung injury. Ann N Y Acad Sci 796:104-112, 1996
15. Benzzaquen LR, Nicholson-Weller A, Halperin JA: Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179:985-992, 1994
16. Halperin JA, Taratuska A, Nicholson-Weller A: Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 91:1974-1978, 1993
17. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D: Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in the atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 16:673-677, 1996
18. Hattori R, Hamilton KK, McEver RP, Sims PJ: Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 264:9053-9060, 1989
19. Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, Cohen H, Ward PA, Friedl HP, Warren JS: Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kB activation. Am J Pathol 150:2019-2031, 1997
20. Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS: Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 155:1434-1441, 1995
21. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ: Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 263:18205-18212, 1988
22. Falk RJ, Sisson SP, Dalmasso AP, Kim Y, Michael AF, Vernier RL: Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis 9:121-128, 1987
23. Rosoklija GB, Dwork AJ, Younger DS, Karlikaya G, Latov N, Hays AP: Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol (Berl) 99:55-62, 2000
24. Zhang J, Gerhardinger C, Lorenzi M: Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 51:3499-3504, 2002
25. Qin X, Miwa T, Aktas H, Gao M, Lee C, Qian YM, Morton CC, Shahsafaei A, Song WC, Halperin JA: Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b. Mamm Genome 12:582-589, 2001
26. Qian YM, Qin X, Miwa T, Sun X, Halperin JA, Song WC: Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J Immunol 165:2528-2534, 2000
27. Nangaku M, Meek RL, Pippin J, Gordon KL, Morgan BP, Johnson RJ, Couser WG: Transfected CD59 protects mesangial cells from injury induced by antibody and complement. Kidney Int 50:257-266, 1996
28. Zhao X-j, Zhao J, Zhou Q, Sims PJ: Identity of the residues responsible for the species-restricted complement inhibitory function of human CD59. J Biol Chem 273:10665-10671, 1998
29. Acosta J, Qin X, Halperin J: Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des 10:203-211, 2004
30. Hatanaka M, Seya T, Miyagawa S, Matsumoto M, Hara T, Tanaka K, Shimizu A: Cellular distribution of a GPI-anchored complement regulatory protein CD59: homodimerization on the surface of HeLa and CD59-transfected CHO cells. J Biochem (Tokyo) 123:579-586, 1998
31. Qin X, Krumrei N, Grubissich L, Dobarro M, Aktas H, Perez G, Halperin JA: Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity 18:217-227, 2003
32. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC: Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A 96:628-633, 1999
33. Telen MJ, Green AM: The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood 74:437-441, 1989
34. Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N, et al.: Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 323:1164-1189, 1990
35. Brooimans RA: Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement mediated lysis. Eur J Immunol 22:3135-3140, 1992
36. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF: Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48:1454-1458, 1999
37. Davies CS, Harris CL, Morgan BP: Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects. Int Immunopharmacol 2:1387, 2002
38. Peterson CM, Jones RL, Koenig RJ, Melvin ET, Lehrman ML: Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med 86:425-429, 1977
39. Bem MM, Busick EJ: Disorders of the blood and diabetes. In Joslin's Diabetes Mellitus. Marble A, Ed. Philadelphia, Lea & Febiger, 1985, p. 748
40. Klerx JP, Beukelman CJ, Van Dijk H, Willers JM: Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum. J Immunol Methods 63:215-220, 1983
41. Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 15:44-54, 2001
42. Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ: Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 82:1192-1196, 1993
43. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabo C: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108-113, 2001
44. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
45. Ishii H, Koya D, King GL: Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 76:21-31, 1998
46. Cybulsky AV, Bonventre JV, Quigg RJ, Lieberthal W, Salant DJ: Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury. Kidney Int 38:803-811, 1990
47. Carney DF, Lang TJ, Shin ML: Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol 145:623-629, 1990
48. Niculescu F, Rus H: Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res 24:191-199, 2001
49. Hallett MB, Luzio JP, Campbell AK: Stimulation of Ca2+-dependent chemiluminescence in rat polymorphonuclear leucocytes by polystyrene beads and the non-lytic action of complement. Immunology 44:569-576, 1981
50. Viedt C, Hansch GM, Brandes RP, Kubler W, Kreuzer J: The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-κB and AP-1. FASEB J 14:2370-2372, 2000